Please ensure Javascript is enabled for purposes of website accessibility

Mylan Ramps Up Production of Hydroxychloroquine as a Potential COVID-19 Treatment

By Brian Orelli, PhD - Mar 19, 2020 at 8:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The decades-old malaria drug could help fight the new coronavirus.

Mylan (MYL) has restarted production of its hydroxychloroquine sulfate tablets at its West Virginia manufacturing facility as a potential treatment for COVID-19, the disease caused by the new coronavirus. The company plans to have product available by mid-April and thinks it can ramp up to 50 million tablets, which could treat more than 1.5 million people.

Chloroquine and hydroxychloroquine, a less toxic metabolite of chloroquine, are antiviral medications that are approved to treat malaria. Because it's less toxic and has anti-inflammatory properties, hydroxychloroquine is also approved to treat a pair of auto-immune disorders, lupus erythematosus and rheumatoid arthritis.

An article published in the journal Cell Research in February showed that chloroquine inhibited the 2019-nCoV coronavirus as well as Gilead Sciences' (GILD 0.80%) remdesivir in an experiment testing how well the virus infects cells grown in a laboratory. Gilead is running a late-stage clinical trial of remdesivir as a COVID-19 treatment, but since it hasn't been approved for any diseases, remdesivir isn't as widely available as chloroquine and hydroxychloroquine.

Scientist working in a laboratory

Image source: Getty Images.

This week, some of those same researchers published research in Cell Discovery comparing chloroquine and hydroxychloroquine, showing chloroquine was more active than hydroxychloroquine, but the lower toxicity of hydroxychloroquine could allow it to be dosed at a higher level and make up for the lower activity. The anti-inflammatory property of hydroxychloroquine could also make the drug more effective since some patients with COVID-19 have had overactive immune systems that result in a cytokine storm where the immune system starts attacking the patient's own cells.

Chloroquine and hydroxychloroquine have been around for decades and are available as generics, so Mylan isn't likely to make very much selling generic hydroxychloroquine. Bayer (BAYR.Y -0.97%) is donating 3 million tablets of chloroquine to the U.S. government for potential use as a treatment for COVID-19.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Viatris Inc. Stock Quote
Viatris Inc.
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.08 (0.80%) $0.50
Bayer Stock Quote
$15.23 (-0.97%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.